PDE12 in type 1 diabetes

Hasim Tekin, Knud Josefsen, Lars Krogvold, Knut Dahl-Jørgensen, Ivan Gerling, Flemming Pociot, Karsten Buschard


Type 1 diabetes (T1D) incidence is increased after COVID-19 infection in children under 18 years of age. Interferon-α-activated oligoadenylate synthetase and downstream RNAseL activation degrade pathogen RNA, but can also damage host RNA when RNAseL activity is poorly regulated. One such regulator is PDE12 which degrades 2'-5' oligoadenylate units, thereby decreasing RNAseL activity. We analyzed PDE12 expression in islets from non-diabetic donors, individuals with newly (median disease duration 35 days) and recently (5 years) diagnosed T1D, and individuals with type 2 diabetes (T2D). We also analyzed PDE12 single-nucleotide polymorphisms (SNPs) relative to T1D incidence. PDE12 expression was decreased in individuals with recently diagnosed T1D, in three of five individuals with newly diagnosed T1D, but not in individuals with T2D. Two rare PDE12 SNPs were found to have odds ratios of 1.80 and 1.74 for T1D development. We discuss whether decreased PDE12 expression after COVID-19 infection might be part of the up to 2.5-fold increase in T1D incidence.

Original languageEnglish
Article number18149
JournalScientific Reports
Issue number1
Publication statusPublished - 28 Oct 2022


  • Child
  • Humans
  • Adolescent
  • Diabetes Mellitus, Type 1/genetics
  • Diabetes Mellitus, Type 2/genetics
  • COVID-19/genetics
  • Interferon-alpha
  • RNA


Dive into the research topics of 'PDE12 in type 1 diabetes'. Together they form a unique fingerprint.

Cite this